{"id":"NCT03410992","sponsor":"UCB Biopharma SRL","briefTitle":"A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","officialTitle":"A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-05","primaryCompletion":"2018-12-28","completion":"2020-01-07","firstPosted":"2018-01-25","resultsPosted":"2022-03-04","lastUpdate":"2023-12-20"},"enrollment":435,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis","Moderate to Severe Chronic Plaque Psoriasis","Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Bimekizumab","otherNames":["UCB4940"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"Bimekizumab cohort","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Bimekizumab Escape arm","type":"EXPERIMENTAL"}],"summary":"Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16","timeFrame":"At Week 16","effectByArm":[{"arm":"Placebo (RS)","deltaMin":1.2,"sd":null},{"arm":"Bimekizumab 320 mg Q4W (RS)","deltaMin":90.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":77,"countries":["United States","Australia","Canada","Germany","Hungary","Poland","Russia","South Korea","United Kingdom"]},"refs":{"pmids":["35544084","37950894","39578348","34260044","33549192"],"seeAlso":["https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":86},"commonTop":["Nasopharyngitis","Oral candidiasis","Upper respiratory tract infection","Psoriasis","Seborrhoeic dermatitis"]}}